TruVerifAI

Medical & Pharma

Multi-model AI verification examples for medical & pharma professionals.

The most compelling data point for 1L combinations was the one the report left out

A KRAS G12C oncology briefing buried its strongest evidence under a two-year-old abstract — and inverted survival figures the source data contradict. Here is what four frontier models caught that one missed.

Read the analysis

A GSK pipeline benchmarked against an unmet need that's already been met

GSK's FY 2025 pipeline report positions its MASH assets against an unmet need — but the first oral MASH therapy was approved in 2024, and four models caught what one missed.

Read the analysis

A Moderna vaccine evidence list, frozen at the moment the science moved

A 2026-dated publications page that never mentions the 2024-2025 effectiveness data, the ACIP policy shift, or the discontinued pregnancy recommendation — the context a clinician needs most.

Read the analysis

A request for research on drug-resistant superbugs — built on a treatment map already out of date

When a pharma RFP defines an "unmet need," the framing decides where research money goes. Four models found the clinical gaps one model accepted.

Read the analysis

A drug poster with no competitor on the page: what four AIs found in Novartis's remibrutinib data

Novartis's REMIX poster benchmarks its new CSU drug against placebo alone — naming no rival therapy, no liver-enzyme breakdown, and skipping a 12-fold safety signal. A four-model panel mapped the gaps a single model missed.

Read the analysis

A first-in-class KEYTRUDA win — and the approved rival its press release never names

Merck's KEYNOTE-B96 release announces the first checkpoint regimen to extend survival in platinum-resistant ovarian cancer. Four models, made to disagree, found the competing drug, the toxicity trade-off, and the patient population it left off the page.

Read the analysis

A green-trials story built on a five-year-old benchmark

AstraZeneca's case for decarbonizing clinical trials is directionally sound — but its lead statistic, its climate-health citation, and its equity assumptions are a cycle behind, and four models caught what one accepted.

Read the analysis

What WebMD's 2026 wellness-trends report left out of the budget case

A clinically branded roundup that shapes what employers cover — and what midlife and mental-health patients can access — skips the trial evidence and HRT guidance that decide whether its recommendations hold.

Read the analysis

A "best online therapy" guide that never mentions BetterHelp's FTC settlement

Patients use these rankings to choose crisis care, prescribed medication, and treatment for their kids — so what the guide left out matters as much as what it got wrong.

Read the analysis

An obesity outlook that names a winning drug — but never weighs the catch

IQVIA's 2026 obesity outlook leans on tirzepatide's superiority, yet four frontier models found it skips the catch: muscle loss, adherence churn, and class safety — plus a drug-class error repeated twice.

Read the analysis